Palbo 125mg Capsule

About

Palbociclib is an oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It works by selectively inhibiting CDK4 and CDK6, which are key regulators of cell cycle progression. This inhibition prevents cancer cells from dividing and growing, thereby slowing tumor progression. It is typically used in combination with an aromatase inhibitor or fulvestrant.

This targeted therapy helps to overcome resistance to endocrine therapy by restoring cell cycle control. Clinical studies have demonstrated that adding palbociclib to endocrine therapy significantly prolongs progression-free survival in eligible patients. Its mechanism of action focuses on disrupting the proliferation of cancer cells that rely on CDK4/6 activity for growth, offering a crucial treatment option for this specific subtype of breast cancer.

Uses

• Treatment of HR-positive, HER2-negative advanced breast cancer.
• Used in combination with an aromatase inhibitor as initial endocrine-based therapy.
• Used in combination with fulvestrant after disease progression on endocrine therapy.
• To delay disease progression in metastatic breast cancer.

Directions For Use

Take the capsule orally with food, preferably at the same time each day, as directed by your physician. Do not chew, crush, or open the capsule.

Benefits

• Significantly prolongs progression-free survival.
• Effective in HR-positive, HER2-negative advanced breast cancer.
• Offers a targeted therapy approach.
• Can be used in first-line and second-line settings.
• Improves outcomes when combined with endocrine therapy.
• Oral administration for convenience.

Side Effects

• Neutropenia (low white blood cell count)
• Leukopenia (low total white blood cell count)
• Fatigue
• Nausea
• Stomatitis (mouth sores)
• Diarrhea
• Hair thinning/loss (alopecia)
• Anemia
• Thrombocytopenia (low platelet count)
• Infections
• Rash
• Abnormal liver function tests

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects or interact with the medication.
• Pregnancy - Palbociclib can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least 3 weeks after the last dose.
• Breastfeeding - It is unknown if palbociclib is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for 3 weeks after the last dose.
• Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustments may be necessary.
• Kidney - Use with caution in patients with severe renal impairment; dose adjustments may be necessary.
• Lung - Monitor for signs of interstitial lung disease/pneumonitis; discontinue if confirmed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.